Fed’s Powell opens door to potential rate cuts at Jackson Hole
David Michael Williams, Executive Vice President and Chief Information & Digital Officer at Merck (NSE:PROR) & Co., Inc. (NYSE:MRK), recently made a significant move in the stock market. According to a Form 4 filing with the Securities and Exchange Commission, Williams sold 6,000 shares of Merck common stock on February 13, 2025. The shares were sold at an average price of $85.3428 each, totaling approximately $512,056.
Following this transaction, Williams holds 24,123.316 shares, which include shares acquired through dividend reinvestment. The sale reflects a strategic financial decision by Williams, who retains a substantial stake in the pharmaceutical giant. Notably, Merck maintains a strong dividend track record, having paid dividends for 55 consecutive years with a current yield of 3.78%. InvestingPro subscribers can access 10 additional key insights about Merck’s financial health and market position.
In other recent news, Merck has had several noteworthy developments. Guggenheim maintained a Buy rating on Merck but lowered its price target to $115 due to revised sales estimates for Gardasil. The firm’s analysis suggests a positive long-term outlook for Merck, despite near-term adjustments. In a separate development, Neuphoria Therapeutics announced a $15 million milestone payment from Merck following the initiation of a Phase 2 clinical trial for MK-1167, a potential Alzheimer’s disease treatment.
Furthermore, Bernstein SocGen Group and TD Cowen have also revised their price targets for Merck to $95 and $100 respectively, citing concerns over Gardasil and the upcoming loss of exclusivity for Keytruda. Despite these challenges, Merck has launched a Phase 3 clinical trial for zilovertamab vedotin, a potential treatment for diffuse large B-cell lymphoma, following positive outcomes from a Phase 2 trial. These are the recent developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.